Halozyme Therapeutics Inc
HALO
Company Profile
Business description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Contact
12390 El Camino Real
San DiegoCA92130
USAT: +1 858 794-8889
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
350
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,000.70 | 41.30 | 0.46% |
| CAC 40 | 8,119.84 | 31.54 | -0.39% |
| DAX 40 | 24,274.15 | 14.25 | -0.06% |
| Dow JONES (US) | 48,134.89 | 183.04 | 0.38% |
| FTSE 100 | 9,862.78 | 34.64 | -0.35% |
| HKSE | 25,801.77 | 111.24 | 0.43% |
| NASDAQ | 23,307.62 | 301.26 | 1.31% |
| Nikkei 225 | 50,402.39 | 895.18 | 1.81% |
| NZX 50 Index | 13,508.30 | 174.90 | 1.31% |
| S&P 500 | 6,834.50 | 59.74 | 0.88% |
| S&P/ASX 200 | 8,699.90 | 39.70 | 0.46% |
| SSE Composite Index | 3,917.36 | 26.92 | 0.69% |